

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

L Number	Hits	Search Text	DB	Time stamp
1	12	degenhardt.in. and eickhoff.in.	USPAT; US-PGPUB	2003/03/16 11:41
2	83	((546/189,208,193,153).CCLS.) ((540/481,597).CCLS.) ((544/363,360,364).CCLS.) ((514/311,316,317,318,326,253.07,253.13,217.04).CCLS.)) AND (multidrug\$ OR "multi-drug" OR (multi ADJ drug))	USPAT; US-PGPUB	2003/03/16 11:41
3	332	((546/189,208,193,153).CCLS.) ((540/481,597).CCLS.) ((544/363,360,364).CCLS.) ((514/311,316,317,318,326,253.07,253.13,217.04).CCLS.)) and (piperidine with oxo)	USPAT; US-PGPUB	2003/03/16 11:42
4	3	((546/189,208,193,153).CCLS.) ((540/481,597).CCLS.) ((544/363,360,364).CCLS.) ((514/311,316,317,318,326,253.07,253.13,217.04).CCLS.)) AND (multidrug\$ OR "multi-drug" OR (multi ADJ drug))) and (((546/189,208,193,153).CCLS.) ((540/481,597).CCLS.) ((544/363,360,364).CCLS.) ((514/311,316,317,318,326,253.07,253.13,217.04).CCLS.)) and (piperidine with oxo))	USPAT; US-PGPUB	2003/03/16 11:42

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003

NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS 43 Feb 13 CANCERLIT is no longer being updated
NEWS 44 Feb 24 METADEX enhancements
NEWS 45 Feb 24 PCTGEN now available on STN
NEWS 46 Feb 24 TEMA now available on STN
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 48 Feb 26 PCTFULL now contains images
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:53:32 ON 16 MAR 2003

=> le reg

LE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:53:41 ON 16 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS).

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2003 HIGHEST RN 499099-49-9
DICTIONARY FILE UPDATES: 13 MAR 2003 HIGHEST RN 499099-49-9

Thomas McKenzie 03/16/2003

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading C:\Program Files\Stnexp\Queries\09741272.str



chain nodes :

5 6 7 14 15 16 17 18 19 25 26 27 28 35

ring nodes :

1 2 3 4 8 9 10 11 12 13

ring/chain nodes :

29 30

chain bonds :

1-5 2-25 5-6 6-7 6-11 14-15 14-16 15-17 18-19 25-26 26-35 28-29

ring bonds :

1-2 1-4 2-3 3-4 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

1-2 1-4 2-3 2-25 3-4 6-7 6-11 8-9 8-13 9-10 10-11 11-12 12-13 14-16
15-17 25-26 26-35 28-29

exact bonds :

1-5 5-6 14-15 18-19

G1:[*1-*2],[*3-*4]

G2:[*5],[*6],[*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:CLASS 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 35:CLASS

L1 STRUCTURE UPLOADED

=> is l1

IS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1

SAMPLE SEARCH INITIATED 09:54:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4896 TO ITERATE

20.4% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 93726 TO 102114
PROJECTED ANSWERS: 1 TO 229

L2 1 SEA SSS SAM L1


=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Butanamide, N-[(3S,5S)-1-(1,3-benzodioxol-5-ylmethyl)-5-(1-piperidinylcarbonyl)-3-pyrrolidinyl]-N-[(3-methoxyphenyl)methyl]-3,3-dimethyl- (9CI)

MF C32 H43 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full

FULL SEARCH INITIATED 09:55:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 96444 TO ITERATE

100.0% PROCESSED 96444 ITERATIONS
SEARCH TIME: 00.00.06

103 ANSWERS

L3 103 SEA SSS FUL L1

=> file caold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

149.35

149.56

FILE 'CAOLD' ENTERED AT 09:56:11 ON 16 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGlstry for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3

L4 1 L3

=> d

L4 ANSWER 1 OF 1 CAOLD COPYRIGHT 2003 ACS
AN CA62:14636f CAOLD
TI α -aryl- α -cyano- ω -dialkylaminoalkanoamides
AU Pesson, Marcel
PA Laboratoire Roger Bellon
DT Patent

	PATENT NO.	KIND	DATE			
	-----	-----	----			
PI	FR M3002					
	GB 1008470					
IT	972-04-3	973-33-1	1034-65-7	1034-66-8	1034-67-9	1038-08-0
	1038-09-1	1038-10-4	1038-11-5	1042-07-5	1042-08-6	1042-09-7
	1045-18-7	1045-19-8	1045-20-1	1048-18-6	1048-19-7	1048-20-0
	1134-20-9	1140-94-9	1140-95-0	1147-63-3	1148-51-2	1149-86-6
	1149-93-5	1158-59-4	1158-69-6	1158-70-9	1162-04-5	1162-12-5
	1164-47-2	1164-48-3	1164-49-4	1166-76-3	1167-02-8	1167-03-9
	1167-11-9	1224-20-0	1224-22-2	1227-90-3	1231-27-2	
	1231-28-3	1235-35-4	1235-36-5	1235-37-6	1241-55-0	1241-56-1
	1440-27-3	1440-28-4	1440-29-5	1610-83-9	1610-84-0	1670-04-8
	1670-05-9	1828-55-3	1866-05-3	1875-94-1	1906-61-2	1906-62-3
	1906-63-4	1908-37-8	1908-38-9	2032-67-9	2035-44-1	2141-46-0
	2952-08-1	3473-93-6	3980-99-2	3981-00-8	3981-01-9	3981-02-0
	3981-19-9	4016-58-4	4090-09-9	4556-84-7	7275-82-3	


=> d hitstr

L4 ANSWER 1 OF 1 CAOLD COPYRIGHT 2003 ACS

IT **1167-11-9**

RN 1167-11-9 CAOLD

CN Piperidine, 1-[α -cyano- β -(1-ethyl-2-pyrrolidinyl)hydratropoyl]-
(7CI, 8CI) (CA INDEX NAME)



=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.42

152.98

FILE 'CAPLUS' ENTERED AT 09:57:25 ON 16 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Mar 2003 VOL 138 ISS 12

FILE LAST UPDATED: 14 Mar 2003 (20030314/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L5 27 L3

=> sort py 15

SORT ENTIRE ANSWER SET? (Y)/N:.

PROCESSING COMPLETED FOR L5


L6 27 SORT L5 PY

=> d 1-27 cbib pi hitstr

L6 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2003 ACS

1965:82462 Document No. 62:82462 Original Reference No. 62:14636f-h,14637a-d
 α -Aryl- α -cyano- ω -dialkylaminoalkanoamides. Pesson,
Marcel (laboratoire Roger Bellon). FR M3002 19650118, 35 pp.
(Unavailable). PRIORITY: GB 19620917.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR M3002		19650118	FR	
	GB 1008470			GB	
IT	1167-11-9 , Piperidine, 1-[α -cyano- β -(1-ethyl-2-pyrrolidinyl)hydratropoyl]- (preparation of)				
RN	1167-11-9 CAPLUS				
CN	Piperidine, 1-[α -cyano- β -(1-ethyl-2-pyrrolidinyl)hydratropoyl]- (7CI, 8CI) (CA INDEX NAME)				



L6 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2003 ACS

1969:28834 Document No. 70:28834 2-Azabicyclo[2.2.2]octan-3-one-1-carboxylic acid and derivatives useful as analgesics. Feit, Peter W.; Frey, Hans H. (Loevens Kemiske Fabrik Produktionsaktiesleskab). Brit. GB 1115817 19680529, 8 pp. (English). CODEN: BRXXAA. APPLICATION: GB 19650823. PATENT NO. KIND DATE APPLICATION NO. DATE


PI GB 1115817 19680529 GB 19650823

IT **21121-52-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 21121-52-8 CAPLUS

CN Piperidine, 1-[(2-benzyl-3-oxo-2-azabicyclo[2.2.2]oct-1-yl)carbonyl]-
(8CI) (CA INDEX NAME)



L6 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2003 ACS

1993:35695 Document No. 118:35695 Studies on the synthesis and antibacterial activity of carbapenem derivatives. (I). Oh, Chang Hyun; Hong, Soon Yung; Cho, Jung Hyuck (Org. Chem. II. Div. Appl. Sci. Eng., Korea Inst. Sci. Technol., Seoul, 136-791, S. Korea). Korean Journal of Medicinal Chemistry, 2(1), 7-16 (English) 1992. CODEN: KJMCE7. ISSN: 1225-0058.


IT 145208-93-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and hydrogenolysis of)

RN 145208-93-1 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-[[5-
[(4-hydroxy-1-piperidinyl)carbonyl]-1-[(4-nitrophenyl)methyl]-3-
pyrrolidinyl]thio]-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester,
[4R-[3(3S*,5S*),4 α ,5 β ,6 β (R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2003 ACS

1994:509676 Document No. 121:109676 Preparation of N-(2-oxoethyl)amino acid derivatives and peptides as immunosuppressants. Connell, Richard D.; Osterman, David D.; Katz, Michael E. (Miles Inc., USA). Eur. Pat. Appl. EP 564924 A2 19931013, 96 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1993-105035 19930326. PRIORITY: US 1992-864998 19920408; US 1992-981565 19921125.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 564924	A2	19931013	EP 1993-105035	19930326
EP 564924	A3	19931229		
EP 564924	B1	19980909		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2091194	AA	19931009	CA 1993-2091194	19930308
AT 170870	E	19980915	AT 1993-105035	19930326
ES 2119826	T3	19981016	ES 1993-105035	19930326
AU 9336773	A1	19931014	AU 1993-36773	19930406
AU 666179	B2	19960201		
JP 06041064	A2	19940215	JP 1993-106160	19930408
US 5686424	A	19971111	US 1995-431390	19950428
IT 156800-93-0P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of, as immunosuppressant)				
RN	156800-93-0 CAPLUS			
CN	Piperidine, 1-[[1-[2-oxo-2-(3,4,5-trimethoxyphenyl)ethyl]-2-pyrrolidinyl]carbonyl]-4-phenyl-, (S)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.



L6 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2003 ACS

1994:270133 Document No. 120:270133 Preparation of carbostyryl derivatives as blood platelet aggregation inhibitors.. Sato, Seiji; Yukawa, Hirotaka; Kihara, Yoshito; Koga, Nobuyuki; Saito, Mashiro; Nishi, Takao (Otsuka Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 9304042 A1 19930304, 218 pp. DESIGNATED STATES: W: AU, CA, KR, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1992-JP1041 19920818. PRIORITY: JP 1991-211268 19910823.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9304042	A1	19930304	WO 1992-JP1041	19920818
W: AU, CA, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
CA 2093633	AA	19930224	CA 1992-2093633	19920818
AU 9224292	A1	19930316	AU 1992-24292	19920818
AU 653060	B2	19940915		
EP 569592	A1	19931118	EP 1992-917806	19920818
R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 05194405	A2	19930803	JP 1992-221206	19920820
US 5506239	A	19960409	US 1993-39301	19930422
US 5658926	A	19970819	US 1995-541579	19951010


IT 151641-21-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as blood platelet aggregation inhibitor)

RN 151641-21-3 CAPLUS

CN Piperidine, 1-[[1-[4-[(1,2-dihydro-2-oxo-6-quinolinyl)oxy]butyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]-, (2S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L6 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2003 ACS

1995:740893 Document No. 123:142994 Coupling reagent and method for coupling amines with carboxylic acids.. Desai, Manoj C. (Pfizer Inc., USA). Eur. Pat. Appl. EP 623589 A1 19941109, 22 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1994-302708 19940415. PRIORITY: US 1993-56261 19930430.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 623589	A1	19941109	EP 1994-302708	19940415
	EP 623589	B1	19981223		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5416193	A	19950516	US 1993-56261	19930430
	AT 174901	E	19990115	AT 1994-302708	19940415
	ES 2124843	T3	19990216	ES 1994-302708	19940415
	US 5616687	A	19970401	US 1995-435904	19950505
IT	166438-01-3P				
	RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)				
	(product; solid-phase EDC coupling reagent for amines with carboxylic acids)				
RN	166438-01-3 CAPLUS				
CN	Isoquinoline, 1,2,3,4-tetrahydro-2-[[5-oxo-4-phenyl-1-(phenylmethyl)-2-pyrrolidinyl]acetyl]- (9CI) (CA INDEX NAME)				



L6 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2003 ACS

1995:731510 Document No. 123:144639 Preparation of peptide analog inhibitors of farnesyl protein transferase.. Patel, Dinesh V.; Kline, Toni B.; Meyers, Chester A.; Leftheris, Katerina; Bhide, Rajeev S. (Bristol-Myers Squibb Co., USA). Eur. Pat. Appl. EP 618221 A2 19941005, 110 pp.
 DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1994-302255 19940329. PRIORITY: US 1993-42377 19930402; US 1993-85338 19930629.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 618221	A2	19941005	EP 1994-302255	19940329
EP 618221	A3	19950215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2118985	AA	19941003	CA 1994-2118985	19940314
IL 108999	A1	19990714	IL 1994-108999	19940316
ZA 9401902	A	19941014	ZA 1994-1902	19940317
NO 9401181	A	19941003	NO 1994-1181	19940330
FI 9401519	A	19941003	FI 1994-1519	19940331
AU 9459184	A1	19941006	AU 1994-59184	19940331
AU 679716	B2	19970710		
CN 1098408	A	19950208	CN 1994-103570	19940331
HU 68080	A2	19950529	HU 1994-946	19940331
JP 07089935	A2	19950404	JP 1994-65933	19940404

IT **166168-26-9P 166168-63-4P 166168-64-5P**
166373-90-6P 166373-91-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide analog inhibitors of farnesyl protein transferase)

RN 166168-26-9 CAPLUS

CN L-Methionine, 1-(3-mercaptopropyl)-L-prolyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166168-63-4 CAPLUS

CN L-Methionine, 1-(2-amino-3-mercaptopropyl)-L-prolyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166168-64-5 CAPLUS

CN L-Methionine, 1-(2-amino-3-mercaptopropyl)-2-methyl-D-prolyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166373-90-6 CAPLUS


CN L-Methionine, 1-(2-amino-3-mercaptopropyl)-L-prolyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, (R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 166168-63-4

CMF C23 H34 N4 O4 S2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 166373-91-7 CAPLUS


CN L-Methionine, 1-(2-amino-3-mercaptopropyl)-2-methyl-D-prolyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, (R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 166168-64-5

CMF C24 H36 N4 O4 S2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 166169-06-8P 166169-69-3P 166169-71-7P

166170-22-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of peptide analog inhibitors of farnesyl protein transferase)

RN 166169-06-8 CAPLUS

CN L-Methionine, 1-[3-[(triphenylmethyl)thio]propyl]-L-prolyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166169-69-3 CAPLUS

CN L-Methionine, 1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-
[(triphenylmethyl)thio]propyl]-L-prolyl-L-1,2,3,4-tetrahydro-3-
isoquinolinecarbonyl-, methyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 166169-71-7 CAPLUS

CN L-Methionine, 1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-
[(triphenylmethyl)thio]propyl]-2-methyl-D-prolyl-L-1,2,3,4-tetrahydro-3-
isoquinolinecarbonyl-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166170-22-5 CAPLUS

CN L-Methionine, 1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-
[(triphenylmethyl)thio]propyl]-2-methyl-D-prolyl-L-1,2,3,4-tetrahydro-3-
isoquinolinecarbonyl-, (R)- (9CI) (CA INDEX NAME)

L6 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2003 ACS


1995:881293 Document No. 123:286080 Preparation of α -(mercaptoalkyl)-1-piperazineethanamines as inhibitors of farnesyl-protein transferase.

Graham, Samuel L.; Williams, Theresa M. (Merck and Co., Inc., USA). PCT Int. Appl. WO 9500497 A1 19950105, 156 pp. DESIGNATED STATES: W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, US, UZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.

APPLICATION: WO 1994-US5634 19940519. PRIORITY: US 1993-80028 19930618; US 1994-237586 19940511.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9500497	A1	19950105	WO 1994-US5634	19940519
	W:		AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, US, UZ		
	RW:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	CA 2165176	AA	19950105	CA 1994-2165176	19940519
	AU 9470412	A1	19950117	AU 1994-70412	19940519
	AU 675145	B2	19970123		
	EP 703905	A1	19960403	EP 1994-919174	19940519
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE		
	JP 09500109	T2	19970107	JP 1994-502810	19940519
	ZA 9404326	A	19951214	ZA 1994-4326	19940617
	US 5736539	A	19980407	US 1995-549829	19951116
IT	169448-91-3P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of α -(mercaptoalkyl)-1-piperazineethanamines farnesyl-protein transferase inhibitors)				
RN	169448-91-3 CAPLUS				
CN	Carbamic acid, [1-[[4-(1-naphthalenylcarbonyl)-2-(1-piperidinylcarbonyl)-1-piperazinyl]methyl]-2-[(triphenylmethyl)thio]ethyl]-, 1,1-dimethylethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

IT **169448-92-4P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of α -(mercaptoalkyl)-1-piperazineethanamines farnesyl-protein transferase inhibitors)

RN 169448-92-4 CAPLUS

CN 1-Piperazinepropanethiol, β -amino-4-(1-naphthalenylcarbonyl)-2-(1-

piperidinylcarbonyl)-, dihydrochloride, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L6 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2003 ACS

1996:757294 Document No. 126:117844 Synthesis and x-ray analysis of 1-((1S)-phenylethyl)-azetidine-(2R)-piperidinamide. de Gelder, R.; Smits, J. M. M.; Starmans, W. A. J.; Thijs, L.; Zwanenburg, B. (Department Inorganic Chemistry, Nijmegen SONResearch Center, University Nijmegen, Nijmegen, 6525, Neth.). Journal of Chemical Crystallography, 26(9), 639-642 (English) 1996. CODEN: JCCYEV. ISSN: 1074-1542. Publisher: Plenum.


IT **186096-47-9P**

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure of [(phenylethyl)azetidine]piperidinamide)

RN 186096-47-9 CAPLUS

CN Piperidine, 1-[[1-(1-phenylethyl)-2-azetidiny]carbonyl]-, [S-(R*,S*)]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2003 ACS

1997:805736 Document No. 128:61425 Preparation of indolecarboxamidines and analogs as thrombin inhibitors. Koo, Bon Am; Min, Jae Ki; Hong, Woo Sang; Ryu, Eun Jung; Nam, Woong Hyun; Kim, Jong Min (C & C Research Laboratories, S. Korea; Koo, Bon Am; Min, Jae Ki; Hong, Woo Sang; Ryu, Eun Jung; Nam, Woong Hyun; Kim, Jong Min). PCT Int. Appl. WO 9745424 A1 19971204, 257 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-KR100 19970531. PRIORITY: KR 1996-19282 19960531.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9745424	A1	19971204	WO 1997-KR100	19970531
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9730494	A1	19980105	AU 1997-30494	19970531
EP 918768	A1	19990602	EP 1997-925316	19970531
EP 918768	B2	20020109		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
CN 1219932	A	19990616	CN 1997-195005	19970531
CN 1079396	B	20020220		
JP 2000504030	T2	20000404	JP 1997-542065	19970531
JP 3202994	B2	20010827		
AT 211741	E	20020115	AT 1997-925316	19970531
ES 2171945	T3	20020916	ES 1997-925316	19970531
US 6201006	B1	20010313	US 1998-180675	19981113

IT 200183-02-4P 200183-04-6P 200183-27-3P

200183-66-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolecarboxamidines and analogs as thrombin inhibitors)

RN 200183-02-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-piperidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-04-6 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-piperidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-27-3 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-piperidinyl]carbonyl]-4-methoxy-, ethyl ester, [2R-[2α(S*),4α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200183-66-0 CAPLUS

CN 1-Piperidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-piperidinyl]carbonyl]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Thomas McKenzie 03/16/2003

NAME)

Absolute stereochemistry.



IT 200184-59-4P 200184-94-7P 200185-33-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indolecarboxamides and analogs as thrombin inhibitors)

RN 200184-59-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-piperidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-94-7 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-piperidinyl]carbonyl]-4-methoxy-, ethyl ester, [2R-[2 α (S*),4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-33-7 CAPLUS

CN 1-Piperidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-piperidinyl]carbonyl]-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2003 ACS

1997:499168 Document No. 127:190649 Preparation of 9-aralkyl-9-fluorene-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors. Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; Slusarchyk, William A.; Sulsky, Richard B.; Tino, Joseph A. (Bristol-Myers Squibb Co., USA). PCT Int. Appl. WO 9726240 A1 19970724, 615 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-US587 19970113. PRIORITY: US 1996-10346 19960116; US 1996-17224 19960509; US 1996-30370 19961105.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9726240	A1	19970724	WO 1997-US587	19970113
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2236684	AA	19970724	CA 1997-2236684	19970113
AU 9718285	A1	19970811	AU 1997-18285	19970113
AU 716729	B2	20000302		
CN 1209803	A	19990303	CN 1997-191713	19970113
EP 904262	A1	19990331	EP 1997-903805	19970113
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
BR 9707607	A	19990727	BR 1997-7607	19970113
JP 2000502355	T2	20000229	JP 1997-526127	19970113
ZA 9700328	A	19970715	ZA 1997-328	19970115
NO 9803268	A	19980715	NO 1998-3268	19980715


IT 194217-22-6P 194217-64-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 9-aralkyl-9-fluorene-carboxamides and analogs as microsomal triglyceride transfer protein inhibitors)


RN 194217-22-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[1-(phenylmethyl)-2-piperidinyl]carbonyl]-N-[4-[9-[[[(2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluorene-9-yl]butyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 194217-64-6 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[1-(phenylmethyl)-2-piperidinyl]carbonyl]-N-[5-[9-[[2,2,2-trifluoroethyl)amino]carbonyl]-9H-fluoren-9-yl]pentyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2003 ACS

1998:550424 Document No. 129:161449 Carbapenem compounds, use thereof, and intermediate compounds of the same. Matsui, Hiroshi; Kasai, Masayasu (Kyoto Pharmaceutical Industries, Ltd., Japan). PCT Int. Appl. WO 9834936 A1 19980813, 41 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1998-JP446 19980202. PRIORITY: JP 1997-25671 19970207; JP 1997-248903 19970912.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834936	A1	19980813	WO 1998-JP446	19980202
W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
AU 9856806	A1	19980826	AU 1998-56806	19980202
AU 740327	B2	20011101		
BR 9807187	A	20000125	BR 1998-7187	19980202
EP 987267	A1	20000322	EP 1998-901108	19980202
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO	
NZ 337532	A	20010629	NZ 1998-337532	19980202
RU 2178792	C2	20020127	RU 1999-119323	19980202
NO 9903774	A	19990930	NO 1999-3774	19990804
US 6342494	B1	20020129	US 1999-355757	19990804


IT **211238-10-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of antibacterial carbapenem compds. and their intermediates)

RN 211238-10-7 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-4-methyl-3-[[[(3S,5S)-1-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-5-(1-piperidinylcarbonyl)-3-pyrrolidinyl]thio]-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2003 ACS

1998:251317 Document No. 128:319046 Droplet assay system for screening combinatorial libraries. Schreiber, Stuart L.; Shair, Matthew D.; Borchardt, Allen J.; You, Angie J.; Huang, Jing; Foley, Mike; Tan, Derek; Whitesides, George; Jackman, Rebecca J. (President and Fellows of Harvard College, USA). PCT Int. Appl. WO 9816830 A2 19980423, 126 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-US19110 19971015. PRIORITY: US 1996-29128 19961016; US 1997-49864 19970606.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9816830	A2	19980423	WO 1997-US19110	19971015
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9852391	A1	19980511	AU 1998-52391	19971015
IT	206537-47-5P				
	RL: (Synthetic preparation); PREP (Preparation) (droplet assay system for simultaneously assaying combinatorial libraries and identifying compds. of chemical or biol. activities)				
RN	206537-47-5 CAPLUS				
CN	Oxireno[f]-1,2-benzisoxazole-6a(2H)-carboxamide, N-(6-amino-6-oxohexyl)hexahydro-4-hydroxy-2-(phenylmethyl)-3-(1-piperidinylcarbonyl)-, (3S,3aR,4S,4aR,5aS,6aS)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




L6 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2003 ACS

1998:220858 Document No. 128:270614 Preparation of acylpiperazines and related compounds as inhibitors of farnesyl-protein transferase.. Graham, Samuel L.; Williams, Theresa M. (Merck and Co., Inc., USA). U.S. US 5736539 A 19980407, 50 pp., Cont.-in-part of U.S. Ser. No. 237,586, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1995-549829 19951116. PRIORITY: US 1993-80028 19930618; US 1994-237586 19940511; WO 1994-US5634 19940519.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5736539	A	19980407	US 1995-549829	19951116
	WO 9500497	A1	19950105	WO 1994-US5634	19940519
	W:		AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, US, UZ		
	RW:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	ZA 9404326	A	19951214	ZA 1994-4326	19940617
IT	169448-92-4P 205679-13-6P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of acylpiperazines and related compds. as inhibitors of farnesyl-protein transferase)				
RN	169448-92-4 CAPLUS				
CN	1-Piperazinepropanethiol, β -amino-4-(1-naphthalenylcarbonyl)-2-(1-piperidinylcarbonyl)-, dihydrochloride, [R-(R*,R*)]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




● 2 HCl

RN 205679-13-6 CAPLUS

CN 1-Piperazinepropanethiol, β -amino-4-(1-naphthalenylcarbonyl)-2-(1-piperidinylcarbonyl)-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **169448-91-3P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of acylpiperazines and related compds. as inhibitors of farnesyl-protein transferase)

RN 169448-91-3 CAPLUS

CN Carbamic acid, [1-[[4-(1-naphthalenylcarbonyl)-2-(1-piperidinylcarbonyl)-1-piperazinyl]methyl]-2-[(triphenylmethyl)thio]ethyl]-, 1,1-dimethylethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2003 ACS

1999:811204 Document No. 132:49888 Cyclic hydroxamic acids as metalloproteinase inhibitors. Xue, Chu-Baio; Decicco, Carl P.; He, Xiaohua (Du Pont Pharmaceuticals Company, USA). PCT Int. Appl. WO 9965867 A1 19991223, 222 pp. DESIGNATED STATES: W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US13723 19990617. PRIORITY: US 1998-89557 19980617; US 1999-127599 19990402.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9965867	A1	19991223	WO 1999-US13723	19990617
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2333554	AA	19991223	CA 1999-2333554	19990617
AU 9946923	A1	20000105	AU 1999-46923	19990617
EP 1087937	A1	20010404	EP 1999-930371	19990617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002518368	T2	20020625	JP 2000-554694	19990617
US 6429213	B1	20020806	US 1999-335086	19990617


IT 252918-79-9P 252918-80-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic hydroxamic acids as metalloproteinase inhibitors)

RN 252918-79-9 CAPLUS

CN 3-Piperidinecarboxamide, 1-ethyl-N-hydroxy-2-[(4-phenyl-1-piperidinyl)carbonyl]-, (2S,3S)- (9CI) (CA INDEX NAME)



RN 252918-80-2 CAPLUS


CN 3-Piperidinecarboxamide, 1-ethyl-N-hydroxy-2-[(4-phenyl-1-piperidinyl)carbonyl]-, (2S,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 252918-79-9

CMF C20 H29 N3 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L6 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2003 ACS

1999:566029 Document No. 131:199709 Preparation of heterocyclic substituted anilines as calcium channel blockers. Hu, Lain-Yen; Ryder, Todd Robert; Rafferty, Michael Francis (Warner-Lambert Company, USA). PCT Int. Appl. WO 9943658 A1 19990902, 90 pp. DESIGNATED STATES: W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US25007 19981120. PRIORITY: US 1998-PV76141 19980227.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943658	A1	19990902	WO 1998-US25007	19981120

PI WO 9943658 A1 19990902 WO 1998-US25007 19981120

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9916005	A1	19990915	AU 1999-16005	19981120
US 6251919	B1	20010626	US 1999-319900	19990614

IT 241498-89-5P 241498-92-0P 241498-93-1P


241498-94-2P 241498-95-3P 241498-96-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic substituted anilines as calcium channel blockers for treatment of diseases)


RN 241498-89-5 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[1-(3-methylbutyl)-2-piperidinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 241498-92-0 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[4-methyl-1-(3-methylbutyl)-2-piperazinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 241498-93-1 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[1-(3-methylbutyl)-4-(1-methylethyl)-2-piperazinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI)
(CA INDEX NAME)




RN 241498-94-2 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[6-methyl-1-(3-methylbutyl)-2-piperidinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 241498-95-3 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[4-methyl-1-(3-methylbutyl)-2-piperidinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 241498-96-4 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[3-methyl-1-(3-methylbutyl)-2-piperidinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2003 ACS

1999:460402 Document No. 131:87833 Preparation of aromatic compounds having cyclic amino or salts thereof as FXa inhibitors. Nishida, Hidemitsu; Hosaka, Yoshitaka; Miyazaki, Yutaka; Matsusue, Tomokazu; Mukaihiara, Takafumi (Mochida Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 9933805 A1 19990708, 218 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1998-JP6002 19981228. PRIORITY: JP 1997-367538 19971226; JP 1998-311491 19981030. PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9933805 A1 19990708 WO 1998-JP6002 19981228
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2318351 AA 19990708 CA 1998-2318351 19981228
 AU 9916923 A1 19990719 AU 1999-16923 19981228
 EP 1048652 A1 20001102 EP 1998-961642 19981228
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO


IT 229646-63-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of aromatic compds. having cyclic amino or salts thereof as FXa inhibitors)

RN 229646-63-3 CAPLUS

CN 4-Piperidinol, 1-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2003 ACS

2000:881143 Document No. 134:42075 Preparation of novel isoquinoline derivatives as If current inhibitors. Watanabe, Toshihiro; Kakefuda, Akio; Okazaki, Toshio; Masuda, Noriyuki; Wada, Koichi (Yamanouchi Pharmaceutical Co., Ltd., Japan). PCT Int. Appl. WO 2000075133 A1 20001214, 42 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP3564 20000601. PRIORITY: JP 1999-156217 19990603.
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2000075133 A1 20001214 WO 2000-JP3564 20000601
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1186601 A1 20020313 EP 2000-931652 20000601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

IT 312752-42-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoquinoline derivs. as If current inhibitors)

RN 312752-42-4 CAPLUS


CN 1-Pyrrolidinepropanamide, N-1,3-benzodioxol-5-yl-2-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)carbonyl]-, (2S)-, ethanedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 312752-41-3

CMF C26 H31 N3 O6


Absolute stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



L6 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2003 ACS

2000:634147 Document No. 133:362695 Rapid access to enantiopure bicyclic diamines via aza-Diels-Alder reaction of imino amides. Modin, Stefan A.; Andersson, Pher G. (Department of Organic Chemistry, Uppsala University, Uppsala, SE-751 21, Swed.). Journal of Organic Chemistry, 65(20), 6736-6738 (English) 2000. CODEN: JOCEAH. ISSN: 0022-3263. OTHER SOURCES: CASREACT 133:362695. Publisher: American Chemical Society.

IT **307530-55-8P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of enantiopure bicyclic diamines via aza Diels-Alder reaction of chiral [(phenylethyl)imino]acetamides with cyclopentadiene)

RN 307530-55-8 CAPLUS

CN Piperidine, 1-[[[(1R,3R,4S)-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]hept-5-en-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2003 ACS

2000:487670 Document No. 133:237817 Synthesis and biological activity of 4-aminopiperidine derivatives as N-type calcium channel antagonists. Ryder, Todd R.; Hu, Lain-Yen; Rafferty, Michael F.; Feng, M. Rose; Lotarski, Susan M.; Rock, David M.; Stoehr, Sally J.; Taylor, Charles P.; Weber, Mark L.; Miljanich, George P.; Millerman, Elizabeth; Szoke, Balazs G. (Department of Chemistry, Parke-Davis Pharmaceutical Research, Division Of Warner-Lambert Company, Ann Arbor, MI, 48105, USA). Medicinal Chemistry Research, 10(1), 11-18 (English) 2000. CODEN: MCREEB. ISSN: 1054-2523. Publisher: Birkhaeuser Boston.

IT 241498-89-5P 241498-92-0P 241498-93-1P


241498-94-2P 241498-95-3P 241498-96-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and biol. activity of aminopiperidine derivs. as N-type calcium channel antagonists)


RN 241498-89-5 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[1-(3-methylbutyl)-2-piperidinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 241498-92-0 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[4-methyl-1-(3-methylbutyl)-2-piperazinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 241498-93-1 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[1-(3-methylbutyl)-4-(1-methylethyl)-2-piperazinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 241498-94-2 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[6-methyl-1-(3-methylbutyl)-2-piperidinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 241498-95-3 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[4-methyl-1-(3-methylbutyl)-2-piperidinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 241498-96-4 CAPLUS

CN 4-Piperidinamine, N-(3-methyl-2-butenyl)-1-[[3-methyl-1-(3-methylbutyl)-2-piperidinyl]carbonyl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2003 ACS

2001:904160 Document No. 136:20087 Preparation of 4-anilinoquinazoline derivatives for the treatment of tumors. Hennequin, Laurent Francois Andre; Ple, Patrick (Astrazeneca Ab, Swed.; Astrazeneca Uk Limited). PCT Int. Appl. WO 2001094341 A1 20011213, 234 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-GB2424 20010601. PRIORITY: EP 2000-401581 20000606; EP 2001-400297 20010207; EP 2001-400565 20010305.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001094341	A1	20011213	WO 2001-GB2424	20010601
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
IT 379229-45-5P,	(2S)-1-(2-Hydroxyethyl)-2-piperidinocarbonylpyrrolidine			
RL:	RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)			
	(intermediate; preparation of anilinoquinazoline derivs. for treatment of tumors)			
RN 379229-45-5	CAPLUS			
CN Piperidine, 1-[[(2S)-1-(2-hydroxyethyl)-2-pyrrolidinyl]carbonyl]-	(9CI)			
	(CA INDEX NAME)			

Absolute stereochemistry.



IT 379231-65-9P, 4-(2,4-Dichloro-5-methoxyanilino)-7-(2-((2S)-2-(piperidinocarbonyl)pyrrolidin-1-yl)ethoxy)-5-(tetrahydropyran-4-yloxy)quinazoline 379231-76-2P, 4-(2-Bromo-5-methoxyanilino)-7-(2-((2S)-2-(piperidinocarbonyl)pyrrolidin-1-yl)ethoxy)-5-(tetrahydropyran-4-yloxy)quinazoline 379231-90-0P, 4-(2,3-Methylenedioxyanilino)-7-(2-((2S)-2-(piperidinocarbonyl)pyrrolidin-1-yl)ethoxy)-5-(tetrahydropyran-4-yloxy)quinazoline
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(preparation of anilinoquinazoline derivs. for treatment of tumors)

RN 379231-65-9 CAPLUS

CN Piperidine, 1-[[(2S)-1-[2-[[4-[(2,4-dichloro-5-methoxyphenyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 379231-76-2 CAPLUS

CN Piperidine, 1-[[(2S)-1-[2-[[4-[(2-bromo-5-methoxyphenyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 379231-90-0 CAPLUS

CN Piperidine, 1-[[(2S)-1-[2-[[4-(1,3-benzodioxol-4-ylamino)-5-[(tetrahydro-

2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2003 ACS

2001:597978 Document No. 135:166844 Preparation of piperazinyl and piperidinyl ketones useful for treating or preventing neuronal damage and for stimulating nerve growth. Tomlinson, Ronald; Lauffer, David; Mullican, Michael (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2001058891 A2 20010816, 112 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US4210 20010209. PRIORITY: US 2000-PV181944 20000211; US 2000-PV247330 20001110.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001058891	A2	20010816	WO 2001-US4210	20010209
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
EP 1257544	A2	20021120	EP 2001-912714	20010209
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
BR 2001008175	A	20030128	BR 2001-8175	20010209
NO 2002003787	A	20021011	NO 2002-3787	20020809

IT **354563-65-8P 354563-91-0P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of piperazinyl and piperidinyl ketones useful for treating or preventing neuronal damage and for stimulating nerve growth)

RN 354563-65-8 CAPLUS

CN Piperidine, 1-[[(2S)-1-ethyl-2-piperidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354563-91-0 CAPLUS

CN Piperidine, 1-[[(2S)-1-ethyl-2-piperidinyl]carbonyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 354563-71-6P 354563-74-9P 354563-75-0P
354563-90-9P 354563-92-1P 354563-93-2P
354563-94-3P 354563-95-4P 354563-98-7P
354563-99-8P 354564-00-4P 354564-03-7P
354564-06-0P 354564-07-1P 354564-36-6P
354564-39-9P 354564-41-3P 354564-42-4P
354564-67-3P 354564-69-5P 354564-73-1P
354564-74-2P 354564-75-3P 354564-76-4P
354564-77-5P 354564-79-7P 354564-80-0P
354564-82-2P 354564-84-4P 354564-86-6P
354564-88-8P 354564-90-2P 354564-92-4P
354564-94-6P 354564-96-8P 354565-03-0P
354565-05-2P 354565-07-4P 354565-09-6P
354565-11-0P 354565-13-2P 354565-15-4P
354565-17-6P 354565-19-8P 354565-21-2P
354565-23-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperazinyl and piperidinyl ketones useful for treating or preventing neuronal damage and for stimulating nerve growth)

RN 354563-71-6 CAPLUS

CN Piperidine, 1-[[(2S,4R)-4-hydroxy-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354563-74-9 CAPLUS


CN Piperidine, 1-[[(2S)-3-oxo-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 354563-75-0 CAPLUS
CN Piperidine, 1-[[(2S)-3-(methoxyimino)-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 354563-90-9 CAPLUS
CN Piperidine, 4-(diphenylmethyl)-1-[[(2S)-1-ethyl-2-piperidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 354563-92-1 CAPLUS
CN 4-Piperidinemethanol, 1-[[(2S)-1-ethyl-2-piperidinyl]carbonyl]- α -(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354563-93-2 CAPLUS

CN Piperidine, 1-[[(2S)-1-ethyl-2-piperidinyl]carbonyl]-4-[(4-fluorophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 354563-94-3 CAPLUS

CN Piperidine, 4-(4-fluorophenoxy)-1-[[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 354563-95-4 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 354563-98-7 CAPLUS
CN Piperidine, 4-(phenylmethyl)-1-[[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 354563-99-8 CAPLUS
CN Piperidine, 1-[[(2S)-1-ethyl-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 354564-00-4 CAPLUS
CN Piperidine, 4-(phenylmethyl)-1-[[(2R)-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 354564-03-7 CAPLUS
CN Piperidine, 1-[[(2S)-1-(2-phenylethyl)-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 354564-06-0 CAPLUS
CN Piperidine, 1-[[(2S)-1-[(4-fluorophenyl)methyl]-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 354564-07-1 CAPLUS
CN Piperidine, 4-(phenylmethyl)-1-[[(2S)-1-(3-phenylpropyl)-2-pyrrolidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 354564-36-6 CAPLUS
CN Piperidine, 1-[[(2S,4R)-4-methoxy-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1


CRN 354564-35-5
CMF C25 H32 N2 O2

Absolute stereochemistry.



CM 2


CRN 77-92-9
CMF C6 H8 O7



RN 354564-39-9 CAPLUS

CN Acetic acid, [[(3R,5S)-1-(phenylmethyl)-5-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]-3-pyrrolidinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-41-3 CAPLUS

CN Piperidine, 1-[[[(2S)-1-ethyl-2-piperidinyl]carbonyl]-4-[(4-fluorophenyl)methylene]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 354564-42-4 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methylene]-1-[[[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 354564-67-3 CAPLUS

CN Piperidine, 4-(phenylmethyl)-1-[[(1S,5S)-3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-2-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-69-5 CAPLUS

CN Piperidine, 1-[[(2S,3S)-3-methyl-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-73-1 CAPLUS

CN Piperidine, 1-[[(2S)-5-methyl-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-74-2 CAPLUS

CN Piperidine, 1-[[(2R)-2-methyl-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-75-3 CAPLUS

CN Piperidine, 4-(phenylmethyl)-1-[[(2R,5S)-5-phenyl-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-76-4 CAPLUS

CN Piperidine, 1-[[(2S,5R)-1-ethyl-2-azetidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-77-5 CAPLUS

CN Piperidine, 4-(phenylmethyl)-1-[[(2S,5R)-5-phenyl-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-79-7 CAPLUS

CN Piperidine, 4-(phenylmethyl)-1-[[(2S,3S)-3-phenyl-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-80-0 CAPLUS

CN Piperidine, 1-[[(1S,5S)-3-ethyl-3-azabicyclo[3.1.0]hex-2-yl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-82-2 CAPLUS

CN Piperidine, 1-[[(2S,3S)-1-ethyl-3-methyl-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-84-4 CAPLUS

CN Piperidine, 1-[[(2S)-1-ethyl-5-methyl-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-86-6 CAPLUS

CN Piperidine, 1-[[(2R)-1-ethyl-2-methyl-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-88-8 CAPLUS

CN Piperidine, 1-[[(4R)-3-ethyl-4-thiazolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-90-2 CAPLUS

CN Piperidine, 1-[[(2R,5S)-1-ethyl-5-phenyl-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354564-92-4 CAPLUS


CN Piperidine, 1-[[(2S,5R)-1-ethyl-5-phenyl-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 354564-94-6 CAPLUS
CN Piperidine, 1-[[(2S,4S)-1-ethyl-4-phenyl-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 354564-96-8 CAPLUS
CN Piperidine, 1-[[(2S,3S)-1-ethyl-3-phenyl-2-pyrrolidinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354565-03-0 CAPLUS
CN Piperidine, 1-[[(2S)-1-ethyl-2-pyrrolidinyl]carbonyl]-4-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-05-2 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[(2S)-1-(phenylmethyl)-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-07-4 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[(2S)-1-(2-propenyl)-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-09-6 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[(2S)-1-(3-methyl-2-butenyl)-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-11-0 CAPLUS

CN Piperidine, 1-[[(2S)-1-(cyclopropylmethyl)-2-pyrrolidinyl]carbonyl]-4-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-13-2 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[(2S)-1-[(2E)-3-phenyl-2-propenyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 354565-15-4 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[(2S)-1-[(4-fluorophenyl)methyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-17-6 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[(2S)-1-(2-phenylethyl)-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-19-8 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[(2S)-1-[(4-methylphenyl)methyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-21-2 CAPLUS

CN Piperidine, 1-[[(2S)-1-[(3,4-difluorophenyl)methyl]-2-pyrrolidinyl]carbonyl]-4-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-23-4 CAPLUS

CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[[(2S)-1-[(3-fluorophenyl)methyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2003 ACS

2001:283777 Document No. 134:311102 Preparation and formulation of heterocycles as mediators of hedgehog signaling pathways for pharmaceutical and cosmetic uses. Baxter, Anthony David; Boyd, Edward Andrew; Guicherit, Oivin M.; Price, Stephen; Rubin, Lee (Curis, Inc., USA). PCT Int. Appl. WO 2001026644 A2 20010419, 219 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US28579 20001013. PRIORITY: US 1999-PV159417 19991014; US 2000-PV196543 20000411.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001026644	A2	20010419	WO 2000-US28579	20001013
	WO 2001026644	A3	20020418		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1227805	A2	20020807	EP 2000-978225	20001013
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			

IT **334999-15-4P 334999-21-2P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and formulation of pyrrolidines for pharmaceutical and cosmetic uses as mediators of hedgehog signaling pathways)

RN 334999-15-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[[(2S,4S)-1-(1,3-benzodioxol-5-ylmethyl)-4-[(3,3-dimethyl-1-oxobutyl)[(3-methoxyphenyl)methyl]amino]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 334999-21-2 CAPLUS

CN Butanamide, N-[(3S,5S)-1-(1,3-benzodioxol-5-ylmethyl)-5-(1-piperidinylcarbonyl)-3-pyrrolidinyl]-N-[(3-methoxyphenyl)methyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2003 ACS

2002:314910 Document No. 136:340698 Preparation of 2-substituted heterocyclic compounds as regulators of cellular transport proteins. Degenhardt, Charles Raymond; Eickhoff, David Joseph (The Procter & Gamble Company, USA). PCT Int. Appl. WO 2002032868 A2 20020425, 62 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US32524 20011016. PRIORITY: US 2000-PV241127 20001017; US 2000-741272 20001219.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002032868	A2	20020425	WO 2001-US32524	20011016
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002119960	A1	20020829	US 2000-741272	20001219
AU 2002024431	A5	20020429	AU 2002-24431	20011016
IT 417704-72-4P 417704-90-6P 417704-93-9P				
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of 2-substituted heterocyclic compds. as regulators of cellular transport proteins for treating multidrug resistance in cancer patients)			
RN 417704-72-4	CAPLUS			
CN 4-Piperidinecarboxamide, 1-[[1-[(2R)-2-hydroxy-3-(5-quinolinyloxy)propyl]-2-piperidinyl]carbonyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 417704-90-6 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[1-[(2R)-2-hydroxy-3-(5-quinolinylloxy)propyl]-2-piperidinyl]carbonyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 417704-93-9 CAPLUS

CN 2-Piperidinecarboxamide, 1-[[1-[(2R)-2-hydroxy-3-(5-quinolinylloxy)propyl]-2-piperidinyl]carbonyl]-N-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2003 ACS

2002:293442 Document No. 136:325823 Preparation and formulation of proline derivatives as mediators of hedgehog signaling pathways for pharmaceutical and cosmetic uses. Baxter, Anthony D.; Boyd, Edward A.; Guicherit, Oivin M.; Price, Stephen; Rubin, Lee D. (Curis, Inc., USA). PCT Int. Appl. WO 2002030421 A2 20020418, 230 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US32054 20011012. PRIORITY: US 2000-PV240536 20001013.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002030421	A2	20020418	WO 2001-US32054	20011012
WO 2002030421	A3	20020926		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002011713	A5	20020422	AU 2002-11713	20011012
US 2002165221	A1	20021107	US 2001-977096	20011012
IT 334999-15-4P 334999-21-2P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation and formulation of proline derivs. for pharmaceutical and cosmetic uses as mediators of hedgehog signaling pathways)				
RN 334999-15-4 CAPLUS				
CN 3-Piperidinecarboxamide, 1-[[(2S,4S)-1-(1,3-benzodioxol-5-ylmethyl)-4-[(3,3-dimethyl-1-oxobutyl) [(3-methoxyphenyl)methyl]amino]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 334999-21-2 CAPLUS

CN Butanamide, N-[(3S,5S)-1-(1,3-benzodioxol-5-ylmethyl)-5-(1-piperidinylcarbonyl)-3-pyrrolidinyl]-N-[(3-methoxyphenyl)methyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L6 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2003 ACS

2002:256255 Document No. 136:279479 Preparation of piperazin-2-one amides as inhibitors of factor Xa. Zhu, Bing-yan; Su, Ting; Li, Wenhao; Goldman, Erick A.; Zhang, Penglie; Jia, Zhaozhong Jon; Scarborough, Robert M. (Cor Therapeutics, Inc., USA). PCT Int. Appl. WO 2002026734 A1 20020404, 135 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US30313 20011001. PRIORITY: US 2000-PV236393 20000929.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002026734	A1	20020404	WO 2001-US30313	20011001
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002011280	A5	20020408	AU 2002-11280	20011001
IT 406493-60-5P				
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of piperazin-2-one amides as inhibitors of factor Xa)			
RN 406493-60-5	CAPLUS			
CN	Benzenecarboximidamide, 4-[[4-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]-2-oxo-6-(1-piperidinylcarbonyl)-1-piperazinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)			



L6 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2003 ACS

2002:157764 Document No. 136:200201 Preparation of quinazolines as an anti-invasive agent in the containment and/or treatment of solid tumor disease. Hennequin, Laurent Francois Andre; Ple, Patrick; Lambert, Christine Marie Paul (Astrazeneca AB, Swed.; Astrazeneca UK Limited). PCT Int. Appl. WO 2002016352 A1 20020228, 138 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-GB3649 20010815. PRIORITY: EP 2000-402320 20000821; EP 2001-401006 20010419.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002016352	A1	20020228	WO 2001-GB3649	20010815
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001078609	A5	20020304	AU 2001-78609	20010815

IT 401811-65-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of quinazolines as an anti-invasive agent in the containment and/or treatment of solid tumor disease)

RN 401811-65-2 CAPLUS

CN Piperidine, 1-[[[(2S)-1-[2-[[4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

●2 HCl

IT 379229-45-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinazolines as an anti-invasive agent in the containment and/or treatment of solid tumor disease)

RN 379229-45-5 CAPLUS

CN Piperidine, 1-[[(2S)-1-(2-hydroxyethyl)-2-pyrrolidinyl]carbonyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:.

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

86.99

239.97

STN INTERNATIONAL LOGOFF AT 10:00:48 ON 16 MAR 2003